Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

rhBMP-2 cleared for limited clinical trial for spine fusion

Nov. 28, 1996

FDA clears treatment for bulimia

Nov. 27, 1996

Water-soluble fiber introduced in first market for high cholesterol

Nov. 27, 1996

Agreement reached for atorvastatin development in Japan

Nov. 27, 1996

Uropontin and MAbs with potential in osteoporosis available for licensing

Nov. 26, 1996

Somatogen reports plans for Optro

Nov. 26, 1996

Milestone achieved in Millennium/Roche research collaboration

Nov. 25, 1996

Research suggests improved treatment for anemia

Nov. 25, 1996

Zonagen allowed further patent coverage for zona pellucida proteins

Nov. 25, 1996

More antiobesity proteins reported by Lilly

Nov. 25, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.